|
1
|
GLOBOCAN, . Cancer Incidence and Mortality
Worldwide in 2008. http://globocan.iarc.frAccessed. February
??–2009
|
|
2
|
Stock M and Otto F: Gene deregulation in
gastric cancer. Gene. 360:1–19. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zheng L, Wang L, Ajani J and Xie E:
Molecular basis of gastric cancer development and progression.
Gastric Cancer. 7:61–77. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Futreal PA, Coin L, Marshall M, Down T,
Hubbard T, Wooster R, Rahman N and Stratton MR: A census of human
cancer genes. Nat Rev Cancer. 4:177–183. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Scartozzi M, Galizia E, Freddari F,
Berardi R, Cellerino R and Cascinu S: Molecular biology of sporadic
gastric cancer: prognostic indicators and novel therapeutic
approaches. Cancer Treat Rev. 30:451–459. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gumus-Akay G, Unal AE, Elhan AH, Bayar S,
Karadayt K, Sunguroglu A, Kadikiran A and Tukun A: DNA copy number
changes in gastric adenocarcinomas: high resolution-comparative
genomic hybridization study in Turkey. Arch Med Res. 40:551–560.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Syrokou A, Tzanakakis G, Tsegenidis T,
Hjerpe A and Karamanos NK: Effects of glycosaminoglycans on
proliferation of epithelial and fibroblast human malignant
mesothelioma cells: a structure-function relationship. Cell Prolif.
32:85–99. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kirn-Safran C, Farach-Carson MC and Carson
DD: Multifunctionality of extracellular and cell surface heparan
sulfate proteoglycans. Cell Mol Life Sci. 66:3421–3434. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jackson RL, Busch SJ and Cardin AD:
Glycosaminoglycans: molecular properties, protein interactions and
role in physiological processes. Physiol Rev. 71:481–539.
1991.PubMed/NCBI
|
|
10
|
De Cat B and David G: Developmental roles
of the glypicans. Semin Cell Dev Biol. 12:117–125. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Saunders S, Paine-Saunders S and Lander
AD: Expression of the cell surface proteoglycan glypican-5 is
developmentally regulated in kidney, limb, and brain. Dev Biol.
190:78–93. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yayon A, Klagsbrun M, Esko JD, Leder P and
Ornitz DM: Cell surface, heparin-like molecules are required for
binding of basic fibroblast growth factor to its high affinity
receptor. Cell. 64:841–848. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cumberledge S and Reichsman F:
Glycosaminoglycans and WNTs: just a spoonful of sugar helps the
signal go down. Trends Genet. 13:421–423. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fuster MM and Esko JD: The sweet and sour
of cancer: glycans as novel therapeutic targets. Nat Rev Cancer.
5:526–542. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hsu HC, Cheng W and Lai PL: Cloning and
expression of a developmentally regulated transcript MXR7 in
hepatocellular carcinoma: biological significance and
temporospatial distribution. Cancer Res. 57:5179–5184.
1997.PubMed/NCBI
|
|
16
|
Ning S, Bin C, Na H, et al: Glypican-3, a
novel prognostic marker of hepatocellular cancer, is related with
postoperative metastasis and recurrence in hepatocellular cancer
patients. Mol Biol Rep. 39:351–357. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ozkan H, Erdal H, Kocak E, Tutkak H,
Karaeren Z, Yakut M and Koklu S: Diagnostic and prognostic role of
serum glypican 3 in patients with hepatocellular carcinoma. J Clin
Lab Anal. 25:350–353. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang L, Liu H, Sun L, Li N, Ding H and
Zheng J: Glypican-3 as a potential differential diagnosis marker
for hepatocellular carcinoma: a tissue microarray-based study. Acta
Histochem. 114:547–552. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu S, Li Y, Chen W, Zheng P, Liu T, He W,
Zhang J and Zeng X: Silencing glypican-3 expression induces
apoptosis in human hepatocellular carcinoma cells. Biochem Biophys
Res Commun. 419:656–661. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li Y and Yang P: GPC5 gene and its related
pathways in lung cancer. J Thorac Oncol. 6:2–5. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Su G, Meyer K, Nandini CD, Qiao D, Salamat
S and Friedl A: Glypican-1 is frequently overexpressed in human
gliomas and enhances FGF-2 signaling in glioma cells. Am J Pathol.
168:2014–2026. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kleeff J, Ishiwata T, Kumbasar A, Friess
H, Buchler MW, Lander AD and Korc M: The cell-surface heparan
sulfate proteoglycan glypican-1 regulates growth factor action in
pancreatic carcinoma cells and is overexpressed in human pancreatic
cancer. J Clin Invest. 102:1662–1673. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Midorikawa Y, Ishikawa S, Iwanari H,
Imamura T, Sakamoto H, Miyazono K, Kodama T, Makuuchi M and
Aburatani H: Glypican-3, overexpressed in hepatocellular carcinoma,
modulates FGF2 and BMP-7 signaling. Int J Cancer. 103:455–465.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Capurro MI, Xiang YY, Lobe C and Filmus J:
Glypican-3 promotes the growth of hepatocellular carcinoma by
stimulating canonical Wnt signaling. Cancer Res. 65:6245–6254.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Filmus J and Selleck SB: Glypicans:
proteoglycans with a surprise. J Clin Invest. 108:497–501. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sung YK, Hwang SY, Farooq M, Kim JC and
Kim MK: Growth promotion of HepG2 hepatoma cells by
antisense-mediated knockdown of glypican-3 is independent of
insulin-like growth factor 2 signaling. Exp Mol Med. 35:257–262.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Williamson D, Selfe J, Gordon T, Lu YJ,
Pritchard-Jones K, Murai K, Jones P, Workman P and Shipley J: Role
for amplification and expression of glypican-5 in rhabdomyosarcoma.
Cancer Res. 67:57–65. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yiu GK, Kaunisto A, Chin YR and Toker A:
NFAT promotes carcinoma invasive migration through glypican-6.
Biochem J. 440:157–166. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
WHO Cancer Fact sheet N°297, . World
Health Organization. http://www.who.int/mediacentre/factsheets/fs297/en/Accessed.
February. 2009
|
|
30
|
Garziera M, De Re V, Geremia S, et al: A
novel CDH1 germline missense mutation in a sporadic gastric cancer
patient in north-east of Italy. Clin Exp Med. 13:149–157. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kang JM, Lee BM, Kim N, Lee HS, Lee HE,
Park JH, Kim JS, Jung HC and Song IS: CDX1 and CDX2 expression in
intestinal metaplasia, dysplasia and gastric cancer. J Korean Med
Sci. 26:647–653. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tsapralis D, Panayiotides I, Peros G,
Liakakos T and Karamitopoulou E: Human epidermal growth factor
receptor-2 gene amplification in gastric cancer using tissue
microarray technology. World J Gastroenterol. 18:150–155. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Furuta K, Arao T, Sakai K, et al:
Integrated analysis of whole genome exon array and
array-comparative genomic hybridization in gastric and colorectal
cancer cells. Cancer Sci. 103:221–227. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Leal MF, Calcagno DQ, Borges da Costa J de
F, Silva TC, Khayat AS, Chen ES, Assumpcao PP, de Arruda Cardoso
Smith M and Burbano RR: MYC, TP53, and chromosome 17 copy-number
alterations in multiple gastric cancer cell lines and in their
parental primary tumors. J Biomed Biotechnol. 2011:6312682011.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ye YW, Wu JH, Wang CM, Zhou Y, Du CY,
Zheng BQ, Cao X, Zhou XY, Sun MH and Shi YQ: Sox 17 regulates
proliferation and cell cycle during gastric cancer progression.
Cancer Lett. 307:124–131. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hileman RE, Fromm JR, Weiler JM and
Linhardt RJ: Glycosaminoglycan-protein interactions: definition of
consensus sites in glycosaminoglycan binding proteins. Bioessays.
20:156–167. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Higashiyama S, Abraham JA and Klagsbrun M:
Heparin-binding EGF-like growth factor stimulation of smooth muscle
cell migration: dependence on interactions with cell surface
heparan sulfate. J Cell Biol. 122:933–940. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jackson SM, Nakato H, Sugiura M, Jannuzi
A, Oakes R, Kaluza V, Golden C and Selleck SB: Dally, a Drosophila
glypican, controls cellular responses to the TGF-beta-related
morphogen. Dpp. Development. 124:4113–4120. 1997.
|
|
39
|
Godin RE, Takaesu NT, Robertson EJ and
Dudley AT: Regulation of BMP7 expression during kidney development.
Development. 125:3473–3482. 1998.PubMed/NCBI
|
|
40
|
Yu W, Inoue J, Imoto I, Matsuo Y, Karpas A
and Inazawa J: GPC5 is a possible target for the 13q31-q32
amplification detected in lymphoma cell lines. J Hum Genet.
48:331–335. 2003.PubMed/NCBI
|
|
41
|
Li Y, Sheu CC, Ye Y, et al: Genetic
variants and risk of lung cancer in never smokers: a genome-wide
association study. Lancet Oncol. 11:321–330. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Li F, Shi W, Capurro M and Filmus J:
Glypican-5 stimulates rhabdomyosarcoma cell proliferation by
activating Hedgehog signaling. J Cell Biol. 192:691–704. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kumar A, White TA, MacKenzie AP, et al:
Exome sequencing identifies a spectrum of mutation frequencies in
advanced and lethal prostate cancers. Proc Natl Acad Sci USA.
108:17087–17092. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lau CS, Yu CB, Wong HK, et al: Allelic
imbalance at 13q31 is associated with reduced GPC6 in Chinese with
sporadic retinoblastoma. Br J Ophthalmol. 94:357–362. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lacrima K: Role of glypican-6 and NG2 as
metastasis promoting factors. Universita' Degli Studi Di
ParmaDottorato di ricerca in Fisiopatologia Sistemica2005,
PubMed/NCBI
|
